Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XC101-D13H
- Development stage
- Phase 1
- Lead developer
- Xoc Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XC101-D13H is an oral therapy being developed by Xoc Pharmaceuticals for the prevention of migraine. It has a novel mechanism of action targeting multiple serotonin receptors. The drug acts as an antagonist at 5-HT2B, 5-HT2C, and 5-HT2A receptors, while functioning as a partial agonist at 5-HT1B, 5-HT1D, and 5-HT1F receptors, and as an agonist at 5-HT7 receptors. This receptor profile was designed to provide therapeutic benefit for migraine prevention while avoiding common serotonergic agonist-driven side effects.
02
Targets
HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR1F (Serotonin 5-HT1F receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)
Beyond the preview
Go deeper on XC101-D13H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XC101-D13H.